Avid Bioservices (CDMO)
(Delayed Data from NSDQ)
$7.35 USD
+0.03 (0.41%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $7.34 -0.01 (-0.14%) 7:58 PM ET
5-Strong Sell of 5 5
F Value D Growth C Momentum F VGM
Avid Bioservices (CDMO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.25 | $16.00 | $7.00 | 67.35% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Avid Bioservices comes to $12.25. The forecasts range from a low of $7.00 to a high of $16.00. The average price target represents an increase of 67.35% from the last closing price of $7.32.
Analyst Price Targets (4 )
Broker Rating
Avid Bioservices currently has an average brokerage recommendation (ABR) of 1.60 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.60 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, three are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 60% and 20% of all recommendations. A month ago, Strong Buy made up 60%, while Buy represented 20%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.60 | 1.60 | 1.60 | 1.60 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/11/2024 | Stephens | Jacob Johnson | Strong Buy | Strong Buy |
12/8/2023 | KeyBanc Capital Markets | Paul Knight | Strong Buy | Strong Buy |
12/8/2023 | Craig-Hallum | Matthew G Hewitt | Not Available | Strong Buy |
9/28/2023 | William Blair | Maxwell A Smock | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.60 |
ABR (Last week) | 1.60 |
# of Recs in ABR | 5 |
Average Target Price | $12.25 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | 0.03 |